Literature DB >> 28054170

Risk factors for unprovoked epileptic seizures in multiple sclerosis: a systematic review and meta-analysis.

Sara Gasparini1,2, Edoardo Ferlazzo1,2, Michele Ascoli1,2, Chiara Sueri2, Vittoria Cianci2, Concetta Russo2, Laura Rosa Pisani3, Pasquale Striano4, Maurizio Elia5, Ettore Beghi6, Carmela Colica7, Umberto Aguglia8,9.   

Abstract

The role of different factors in influencing the risk of seizures during multiple sclerosis (MS) is not known. To perform a systematic review and meta-analysis of risk factors for epilepsy during MS. Pubmed, Google scholar, and Scopus databases were searched. Articles published in English (1986-2016) were included. Nine studies were included (3 retrospective cohort and 6 case-control) enrolling 2845 MS patients (217 with epilepsy; 7.6%). MS patients with epilepsy had a younger age at onset compared to MS patients without seizures (difference in means = -5.42 years, 95% CI -7.19 to -3.66, p < 0.001). Mean EDSS value at inclusion tended to be higher in patients with epilepsy, without reaching statistical significance (difference in means = 0.45, 95% CI -0.01 to 0.91, p = 0.054). No differences were observed in sex distribution (OR = 0.94, 95% CI 0.51-1.72, p = 0.83) and clinical form (OR = 1.03, 95% CI 0.33-3.21, p = 0.96). Two studies evaluated presence and number of cortical lesions as a risk factor for epilepsy in MS using different MRI techniques: in one study, cortical lesions were more frequently observed in patients with epilepsy (OR = 7.06, 95% CI 2.39-20.8; p < 0.001). In the other, cortico-juxtacortical lesions were more frequently observed in patients with epilepsy (OR = 2.6, 95% CI 1.0-6.5; p = 0.047). Studies about risk factors for epilepsy during MS are heterogeneous. Compared to MS patients without seizures, patients with epilepsy have an earlier MS onset and a higher EDSS score after similar disease duration. Clinical form of MS and sex do not predict the appearance of seizures.

Entities:  

Keywords:  Age; Cortical lesion; Epilepsy; Meta-analysis; Multiple sclerosis

Mesh:

Year:  2017        PMID: 28054170     DOI: 10.1007/s10072-016-2803-7

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  28 in total

Review 1.  Multiple sclerosis.

Authors:  Alastair Compston; Alasdair Coles
Journal:  Lancet       Date:  2002-04-06       Impact factor: 79.321

2.  Cortical pathology in multiple sclerosis patients with epilepsy: a 3 year longitudinal study.

Authors:  M Calabrese; P Grossi; A Favaretto; C Romualdi; M Atzori; F Rinaldi; P Perini; M Saladini; P Gallo
Journal:  J Neurol Neurosurg Psychiatry       Date:  2011-09-02       Impact factor: 10.154

3.  Surgical treatment of intractable epilepsy attributable to multiple sclerosis.

Authors:  B J Smith; K Elisevich
Journal:  Neurology       Date:  1998-08       Impact factor: 9.910

4.  Prevalence and prognosis of epilepsy in patients with multiple sclerosis.

Authors:  E Kinnunen; J Wikström
Journal:  Epilepsia       Date:  1986 Nov-Dec       Impact factor: 5.864

5.  Temporal lobe epilepsy as a unique manifestation of multiple sclerosis.

Authors:  Antonio Gambardella; Paola Valentino; Angelo Labate; Grazia Sibilia; Francesca Ruscica; Eleonora Colosimo; Rita Nisticò; Demetrio Messina; Mario Zappia; Aldo Quattrone
Journal:  Can J Neurol Sci       Date:  2003-08       Impact factor: 2.104

6.  Epilepsy and multiple sclerosis in Sicily: a population-based study.

Authors:  Alessandra Nicoletti; Vito Sofia; Roberto Biondi; Salvatore Lo Fermo; Ester Reggio; Francesco Patti; Arturo Reggio
Journal:  Epilepsia       Date:  2003-11       Impact factor: 5.864

Review 7.  Seizures in multiple sclerosis.

Authors:  Marcus Koch; Maarten Uyttenboogaart; Susan Polman; Jacques De Keyser
Journal:  Epilepsia       Date:  2008-03-11       Impact factor: 5.864

8.  Epilepsy in multiple sclerosis: The role of temporal lobe damage.

Authors:  M Calabrese; M Castellaro; A Bertoldo; A De Luca; F B Pizzini; G K Ricciardi; M Pitteri; S Zimatore; R Magliozzi; M D Benedetti; P Manganotti; S Montemezzi; R Reynolds; A Gajofatto; S Monaco
Journal:  Mult Scler       Date:  2016-07-11       Impact factor: 6.312

9.  Comparative clinical characteristics of early- and adult-onset multiple sclerosis patients with seizures.

Authors:  Hacer Durmus; Murat Kurtuncu; Erdem Tuzun; Munevver Pehlivan; Gulsen Akman-Demir; Zuhal Yapıcı; Mefkure Eraksoy
Journal:  Acta Neurol Belg       Date:  2013-05-22       Impact factor: 2.396

10.  Natural history of multiple sclerosis with childhood onset.

Authors:  Christel Renoux; Sandra Vukusic; Yann Mikaeloff; Gilles Edan; Michel Clanet; Bénédicte Dubois; Marc Debouverie; Bruno Brochet; Christine Lebrun-Frenay; Jean Pelletier; Thibault Moreau; Catherine Lubetzki; Patrick Vermersch; Etienne Roullet; Laurent Magy; Marc Tardieu; Samy Suissa; Christian Confavreux
Journal:  N Engl J Med       Date:  2007-06-21       Impact factor: 91.245

View more
  5 in total

1.  News on the journal Neurological Sciences in 2017.

Authors:  Ilaria Di Donato; Antonio Federico
Journal:  Neurol Sci       Date:  2018-01       Impact factor: 3.307

2.  Is There a Relationship Between Multiple Sclerosis and Epilepsy? If So What Does It Tell Us About Epileptogenesis?

Authors:  Alison Pack
Journal:  Epilepsy Curr       Date:  2018 Mar-Apr       Impact factor: 7.500

Review 3.  From the Molecular Mechanism to Pre-clinical Results: Anti-epileptic Effects of Fingolimod.

Authors:  Yam Nath Paudel; Efthalia Angelopoulou; Christina Piperi; Vadym Gnatkovsky; Iekhsan Othman; Mohd Farooq Shaikh
Journal:  Curr Neuropharmacol       Date:  2020       Impact factor: 7.363

4.  The prevalence of epileptic seizures in multiple sclerosis in a large tertiary hospital in Australia.

Authors:  Suyi Ooi; Tomas Kalincik; Piero Perucca; Mastura Monif
Journal:  Mult Scler J Exp Transl Clin       Date:  2021-02-24

Review 5.  A global view of comorbidity in multiple sclerosis: a systematic review with a focus on regional differences, methodology, and clinical implications.

Authors:  Larissa Hauer; Julian Perneczky; Johann Sellner
Journal:  J Neurol       Date:  2020-07-27       Impact factor: 4.849

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.